Troponin dependent 30-day mortality in patients with acute pulmonary embolism

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 989 KB, PDF-dokument

Background: Troponin concentrations above upper reference are associated with increased mortality in patients with pulmonary embolism (PE). We aimed to assess whether risk of 30-day mortality increases in a dose-response relationship with concentration of troponin. Methods: Using Danish national registries, we identified patients ≥ 18 years of age hospitalized with first-time PE between 2013 and 2018 and available troponin measurements − 1/+1 day from admission. Patients were stratified into quintiles by increasing troponin concentration. Risk of 30-day mortality was assessed performing cumulative mortality curves and Cox regression model comparing the troponin quintiles. Results: We identified 5,639 PE patients of which 3,278 (58%) had a troponin concentration above upper reference. These patients were older (74 years), 50% male and with heavier comorbidity compared to patients with non-elevated troponin. We found increasing 30-day mortality with increasing troponin concentration (1% in 1st quintile (95% CI 0.5–1.5%), 2% in 2nd quintile (95% CI 1-2.5%), 8% in 3rd quintile (95% CI 5–9%), 11% in 4th quintile (95% CI 9–13%) and 15% in 5th quintile (95% CI 13–16%), confirmed in a Cox model comparing 1st quintile with 2nd quintile (HR 1.09; 95% CI 0.58–2.02), 3rd quintile (HR 3.68; 95% CI 2.20–6.15), 4th quintile (HR 5.51; 95% CI 3.34–9.10) and 5th quintile (HR 8.09; 95% CI 4.95–13.23). Conclusion: 30-day mortality was strongly associated with troponin concentration useful for improving risk stratification, treatment strategies and outcomes in PE patients.

OriginalsprogEngelsk
TidsskriftJournal of Thrombosis and Thrombolysis
Vol/bind56
Udgave nummer3
Sider (fra-til)485-494
Antal sider10
ISSN0929-5305
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
All authors declare no conflicts of interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher Copyright:
© 2023, The Author(s).

ID: 365709705